tiprankstipranks
Advertisement
Advertisement

RXST Stock Latest News

RxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors
Company AnnouncementsRxSight’s Long-Term Lens Study: What Ongoing Results Could Mean For RXST Investors
11d ago
RXST
RxSight price target lowered to $7 from $8 at Stifel
PremiumThe Fly
RxSight price target lowered to $7 from $8 at Stifel
13d ago
RXST
Rxsight’s Earnings Call: Alcon Deal vs. Headwinds
PremiumCompany Announcements
Rxsight’s Earnings Call: Alcon Deal vs. Headwinds
14d ago
RXST
RxSight: Guidance Withdrawal and Strategy Reset Prompt Travis Steed to Maintain Sell Rating Amid Near-Term Execution Risks
PremiumRatings
RxSight: Guidance Withdrawal and Strategy Reset Prompt Travis Steed to Maintain Sell Rating Amid Near-Term Execution Risks
17d ago
RXST
RxSight price target raised to $6.30 from $5.50 at UBS
PremiumThe Fly
RxSight price target raised to $6.30 from $5.50 at UBS
17d ago
RXST
Ryan Zimmerman Reiterates Hold on RxSight Amid Weak Core Trends and Heightened Visibility Risks
PremiumRatingsRyan Zimmerman Reiterates Hold on RxSight Amid Weak Core Trends and Heightened Visibility Risks
17d ago
RXST
RxSight says withdrawing guidance, will resume formal guidance in 2027
Premium
The Fly
RxSight says withdrawing guidance, will resume formal guidance in 2027
17d ago
RXST
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
Premium
The Fly
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
18d ago
RXST
RxSight resumed with a Neutral at UBS
PremiumThe Fly
RxSight resumed with a Neutral at UBS
26d ago
RXST
RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
PremiumThe Fly
RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
1M ago
RXST
TARS
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
PremiumThe Fly
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
2M ago
RXST
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
PremiumThe Fly
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
2M ago
RXST
RxSight price target lowered to $6.50 from $7.50 at Jefferies
PremiumThe FlyRxSight price target lowered to $6.50 from $7.50 at Jefferies
2M ago
RXST
RxSight price target lowered to $6.50 from $8 at BofA
Premium
The Fly
RxSight price target lowered to $6.50 from $8 at BofA
2M ago
RXST
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
Premium
Ratings
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
2M ago
RXST
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
PremiumCompany Announcements
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
2M ago
8K
RXST
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
PremiumThe Fly
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
2M ago
ALC
RXST
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
PremiumThe Fly
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
2M ago
ALC
RXST
RxSight Stockholders Back Leadership at 2026 Annual Meeting
PremiumCompany Announcements
RxSight Stockholders Back Leadership at 2026 Annual Meeting
2M ago
8K
RXST
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
PremiumClass ActionRxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
3M ago
RXST
RxSight Earnings Call Balances Growth With Headwinds
Premium
Company Announcements
RxSight Earnings Call Balances Growth With Headwinds
3M ago
RXST
RxSight price target lowered to $11 from $13 at Needham
Premium
The Fly
RxSight price target lowered to $11 from $13 at Needham
4M ago
RXST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >